Leading science, pioneering therapies

CRM Publications

Found 14 results
Filters: Keyword is Heterozygote  [Clear All Filters]
2009
de Sousa P, Gardner J, Sneddon S, Pells S, Tye BJorgensen, Dand P, Collins DM, Stewart K, Shaw L, Przyborski S et al..  2009.  Clinically failed eggs as a source of normal human embryo stem cells.Stem Cell Res. 2(3):188-97.
2006
Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AG, Withers DJ, Vanhaesebroeck B.  2006.  Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation.Nature. 441(7091):366-70.
Musa H, Meek S, Gautel M, Peddie D, Smith AG, Peckham M.  2006.  Targeted homozygous deletion of M-band titin in cardiomyocytes prevents sarcomere formation.J Cell Sci. 119(Pt 20):4322-31.
2004
Pall GS, Wallis J, Axton RA, Brownstein DG, Gautier P, Buerger K, Mulford C, Mullins JJ, Forrester LM.  2004.  A novel transmembrane MSP-containing protein that plays a role in right ventricle development.Genomics. 84(6):1051-9.
2003
Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AG, Hunter GD, McLean JS, McGarry F et al..  2003.  Essential role for proteinase-activated receptor-2 in arthritis.J Clin Invest. 111(1):35-41.
2002
Houzelstein D, Bullock SL, Lynch DE, Grigorieva EF, Wilson V, Beddington RS.  2002.  Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4.Mol Cell Biol. 22(11):3794-802.
Kawaguchi J, Wilson V, Mee PJ.  2002.  Visualization of whole-mount skeletal expression patterns of LacZ reporters using a tissue clearing protocol.Biotechniques. 32(1):66,68-70,72-3.
1999
Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, Smith AG, Rabbitts TH.  1999.  The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.EMBO J. 18(13):3564-74.
1998
Butcher JW, De Felipe C, Smith AG, Hunt SP, Paton JF.  1998.  Comparison of cardiorespiratory reflexes in NK1 receptor knockout, heterozygous and wild-type mice in vivo.J Auton Nerv Syst. 69(2-3):89-95.
Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR.  1998.  Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.J Hypertens. 16(5):635-43.
1995
Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, Mullins JJ.  1995.  A genetic model of malignant phase hypertension in rats.Kidney Int. 47(2):529-35.
Zmuidzinas A, Fischer KD, Lira SA, Forrester LM, Bryant S, Bernstein A, Barbacid M.  1995.  The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro.EMBO J. 14(1):1-11.
1994
Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJ, Williams BC, Mullins JJ.  1994.  Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats.Kidney Int. 46(6):1528-32.
1993
Samuel K, Clarke AR, Ansell JD, Hooper ML.  1993.  Age-dependent selection against hypoxanthine phosphoribosyl transferase-deficient cells in mouse haematopoiesis.Development. 118(3):859-63.